Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 1/Phase 2Diagnosis: Solid Tumor/Phase INCT ID: NCT01928394
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-474
To investigate the safety and efficacy of Nivolumab as a single agent or in combination with Ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), and small cell lung cancer (SCLC) Bladder Cancer (BC) and Ovarian Cancer (OC).
Conducting Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute
Overall PI: Patrick Ott, MD,
Dana Farber Cancer Institute
Contacts: Dana-Farber Cancer Institute:
Andrew Wolanski, 617-632-6623,